Jefferies upgraded Nevro from Underperform to Hold and set a new price target of $5.85 from $4.50 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2025 | $4.50 → $5.85 | Underperform → Hold | Jefferies |
| 2/7/2025 | $6.00 → $5.85 | Neutral → Overweight | Piper Sandler |
| 12/3/2024 | $5.00 | Equal Weight | Wells Fargo |
| 12/2/2024 | $9.00 → $4.00 | Equal-Weight → Underweight | Morgan Stanley |
| 8/9/2024 | Sell → Neutral | Citigroup | |
| 8/8/2024 | Underperform → Peer Perform | Wolfe Research | |
| 8/7/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 8/7/2024 | Neutral → Underweight | JP Morgan |
REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free
AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.
REDWOOD CITY, Calif., Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on January 7, 2025, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 21,026 shares of Nevro's common stock to 10 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material induceme
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)
4 - NEVRO CORP (0001444380) (Issuer)